These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 25387446)

  • 21. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
    Somerville L; Bardelas J; Viegas A; D'Andrea P; Blogg M; Peachey G
    Curr Med Res Opin; 2014 Jan; 30(1):59-66. PubMed ID: 24028677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pediatric Asthma--do we need more innovation for treatment?
    Riedler J
    Pediatr Allergy Immunol; 2014 Feb; 25(1):19-20. PubMed ID: 24588482
    [No Abstract]   [Full Text] [Related]  

  • 23. The relationship between allergen immunotherapy and omalizumab for treating asthma.
    Braido F; Corsico A; Rogkakou A; Ronzoni V; Baiardini I; Canonica GW
    Expert Rev Respir Med; 2015 Apr; 9(2):129-34. PubMed ID: 25578528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of active B cells in allergen immunotherapy.
    Celiksoy MH; Sancak R; Yildiran A
    Allergol Immunopathol (Madr); 2017; 45(5):439-444. PubMed ID: 28236542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy in all aspects.
    Hanci D; Şahin E; Muluk NB; Cingi C
    Eur Arch Otorhinolaryngol; 2016 Jun; 273(6):1347-55. PubMed ID: 25673026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential treatments for food allergy.
    Albin S; Nowak-Węgrzyn A
    Immunol Allergy Clin North Am; 2015 Feb; 35(1):77-100. PubMed ID: 25459578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects.
    Busse W; Spector S; Rosén K; Wang Y; Alpan O
    J Allergy Clin Immunol; 2013 Aug; 132(2):485-6.e11. PubMed ID: 23591271
    [No Abstract]   [Full Text] [Related]  

  • 28. Patient selection for subcutaneous versus sublingual immunotherapy.
    Larenas-Linnemann D
    Curr Opin Allergy Clin Immunol; 2015 Dec; 15(6):588-95. PubMed ID: 26485098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allergen immunotherapy for the treatment of respiratory allergies in the elderly.
    Hur GY; Lee JH; Park HS
    Curr Opin Allergy Clin Immunol; 2017 Aug; 17(4):304-308. PubMed ID: 28525399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy in allergic rhinitis and lower airway outcomes.
    Cardona V; Luengo O; Labrador-Horrillo M
    Allergy; 2017 Jan; 72(1):35-42. PubMed ID: 27439141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel microcrystalline tyrosine-adsorbed, mite-allergoid subcutaneous immunotherapy: 1-year follow-up report.
    Roger A; Depreux N; Jurgens Y; Serra AT; Heath MD; Garcia G; Skinner MA
    Immunotherapy; 2016 Oct; 8(10):1169-74. PubMed ID: 27388990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful desensitization of three patients with hypersensitivity reactions to omalizumab.
    Owens G; Petrov A
    Curr Drug Saf; 2011 Nov; 6(5):339-42. PubMed ID: 22424542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omalizumab and hypersensitivity reactions.
    Shankar T; Petrov AA
    Curr Opin Allergy Clin Immunol; 2013 Feb; 13(1):19-24. PubMed ID: 23242113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of omalizumab therapy on allergic rhinitis: a pilot study.
    Masieri S; Cavaliere C; Begvarfaj E; Rosati D; Minni A
    Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5249-5255. PubMed ID: 28051241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Preventive effects of allergen immunotherapy to pneumallergens].
    Bougard N; Piette V; Schleich F; Louis R
    Rev Med Liege; 2024 Jun; 79(5-6):405-410. PubMed ID: 38869131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of systemic allergic reactions to allergen immunotherapy in a pediatric allergy clinic in Turkey.
    Bahceci Erdem S; Nacaroglu HT; Karaman S; Unsal Karkıner CS; Gunay I; Dogan D; Asilsoy S; Altınoz S; Can D
    Int J Pediatr Otorhinolaryngol; 2016 May; 84():55-60. PubMed ID: 27063754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toll-like receptors as targets for allergen immunotherapy.
    Aryan Z; Rezaei N
    Curr Opin Allergy Clin Immunol; 2015 Dec; 15(6):568-74. PubMed ID: 26418475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omalizumab treatment in a child with severe asthma and multiple steroid-induced morbidities.
    Rizk C; Ring A; Santucci S; MacLusky I; Karsh J; Yang WH
    Ann Allergy Asthma Immunol; 2012 Sep; 109(3):222-3. PubMed ID: 22920081
    [No Abstract]   [Full Text] [Related]  

  • 40. Omalizumab: just what we needed.
    Torres-Borrego J
    Allergol Immunopathol (Madr); 2014; 42(1):1-2. PubMed ID: 24529608
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.